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In this work the effect of the neurotoxic amino acid sequence, Aβ25–35 , on brain mito-
chondrial permeability transition pore (PTP) was studied. For the purpose, the mitochon-
drial transmembrane potential (∆Ψm), mitochondrial respiration and the calcium fluxes
were examined. It was observed that Aβ25–35, in the presence of Ca2+, decreased the ∆Ψm,
the capacity of brain mitochondria to accumulate calcium and led to a complete uncoupling
of the respiration. However, the reverse sequence of the peptide Aβ25–35 (Aβ35–25) did not
promote the PTP. The alterations promoted by Aβ35–25 andor Ca2+ could be reversed
when Ca2+ was removed by EGTA or when ADP plus oligomycin were present. The pre-
treatment with CsA or ADP plus oligomycin prevented the ∆Ψm drop and preserved the
capacity of mitochondria to accumulate Ca2+. These results suggest that Aβ25–35 can pro-
mote the PTP induced by Ca2+.
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INTRODUCTION
Amyloid plaque, a pathological marker of Alzheimer’s disease (AD), is composed
primarily of amyloid beta peptide (Aβ ) (Glenner, 1988). Aβ is an amphipathic, 39-
to 42-residue peptide, which is derived from the transmembrane amyloid precursor
protein by proteolytic cleavage (Selkoe et al., 1995). A smaller, 11-residue fragment
of Aβ (Aβ24–35) possesses much of the biological activity of the full-length peptide.
In ûitro investigations provided firm pharmacological data on dose- (Pereira et al.,
1998; 1999) and conformation-dependent (Pike and Cotman, 1993) neurotoxic
potentials of Aβ . There are several studies suggesting that oxidative stress and
altered energy metabolism are involved in the pathogenesis of AD (Smith et al.,
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1991; Behl, 1999). Postmortem studies (Kish et al., 1992) demonstrate a decrease in
cytochrome oxidase activity in AD brains. However, the critical step of how Aβ
fragments induce cytotoxicity, directly via oxidative mechanisms, is still to be ascer-
tained. According to the model reported by Hensley et al. (1994) distortions of the
electronic structure of Aβ may result in ‘‘radicalization’’ of the peptide and Aβ itself
can act as a free radical. It has been suggested that internalized Aβ , through intimate
contacts with intracellular recognition sites, directly damages the membranes of
intracellular organelles, such as those involved in the respiratory chain of the mito-
chondria (Pike and Cotman, 1993). Damage to mitochondrial membranes enhances
the production of ROS and compromises neurons by energy depletion. Pereira et
al. (1999) showed in PC12 cells that, Aβ induces mitochondrial dysfunction and
impairment of glycolysis, leading to ATP depletion, by a mechanism involving the
generation of ROS.
Mitochondria have a dual importance in the process of oxidative stress. They
are probably the most important source of increased free radical production and
thus play a crucial role in generating oxidative stress (Boveris et al., 1972; Loschen
et al., 1974). On the other hand, mitochondria are one of the possible targets by
which oxidative stress exerts its effects on cellular deterioration (Bindoli, 1988), and
this is believed to play an important role in neurodegeneration (Beal, 1996). A poten-
tially central factor in cell death in neurodegeneration is the permeability transition
pore (PTP) (Kim et al., 1999; Brustovetsky and Dubinsky, 2000). The PTP is a
nonselective, high conductance channel that spans the inner and outer mitochondrial
membrane (Bernardi et al., 1994; Zoratti and Szabo, 1995). Experimentally, induc-
tion of the PTP is characterized by an abrupt swelling and depolarization of mem-
brane potential accompanied by the efflux of mitochondrial calcium, GSH, and
NAD(P)H (Bernardi, 1992; Petronilli et al., 1994), all of which are inhibited by the
immunosuppressant cyclosporin A (CsA) (Broekemeier et al., 1989).
The aim of the present study was to investigate the effects of Aβ25–35 on the
PTP of brain mitochondria. Mitochondrial transmembrane potential, mitochondrial
respiration and calcium fluxes were the parameters examined.
MATERIALS AND METHODS
Chemicals
Aβ25–35 and Aβ35–25 were obtained from Bachem AG (Bubendorf, Germany).
Protease (Subtilisin, Carlsberg) type VIII was obtained from Sigma. Digitonin was
obtained from Calbiochem. All the other chemicals were of the highest grade of
purity commercially available.
Isolation of Brain Mitochondria
Brain mitochondria were isolated from male Wistar rats (six weeks) by a
method previously described (Rosenthal et al., 1987), with slight modifications. The
rats were killed by decapitation, and the brains were rapidly removed and homogen-
ized at 4°C in 10 ml of isolation medium (225 mM mannitol, 75 mM sucrose, 5 mM
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Hepes, 1 mM EGTA, 1 mgml bovine serum albumin, pH 7.4) containing 5 mg of
the bacterial protease type VIII (Subtilsin). Brain homogenates were brought to
30 ml and then centrifuged at 2000g for three minutes. The pellet was resuspended
in 10 ml of the isolation medium containing 0.02% digitonin (which free mitochond-
ria from the synaptosomal fraction) and centrifuged at 12,000g for eight minutes.
The mitochondrial pellet was resuspended in 10 ml of medium and recentrifuged at
12,000g for ten minutes. Finally, the mitochondrial pellet was resuspended in 300 µl
of resuspension medium (225 mM mannitol, 75 mM sucrose, 5 mM Hepes, pH 7.4).
Mitochondrial protein was determined by the biuret method calibrated with bovine
serum albumin (Gornall et al., 1949).
Membrane Potential (∆Ψm) Measurements
The mitochondrial transmembrane potential was monitored by evaluating
transmembrane distribution of TPP+ (tetraphenylphosphonium) with a TPP+-selec-
tive electrode prepared according to Kamo et al. (1979) using a calomel electrode as
reference.
Reactions were carried out in a chamber with magnetic stirring in 1 ml of the
standard medium supplemented with 3 µM TPP+. The experiments were started by
adding 5 mM succinate to mitochondria in suspension at 0.8 mg proteinml. After
a steady-state distribution of TPP+ had been reached (ca. two minutes of recording),
Ca2+ was added and ∆Ψm fluctuations recorded. Membrane potential was estimated
from the decrease of TPP+ concentration in the reaction medium as described else-
where (Moreno and Madeira, 1991). Aβ25–35 (50, 100 µM) was incubated five
minutes before succinate addition, while 0.85 µM CsA and 2 µgml oligomycin plus
1 mM ADP were added for two minutes prior Aβ25–35 pre-incubation or mitochond-
ria energization.
Mitochondrial Respiration
Oxygen consumption of isolated mitochondria was monitored polaro-
graphically with a Clark oxygen electrode (Estabrook, 1967) connected to a suitable
recorder in a 1 ml thermostated water-jacket closed chamber with magnetic stirring.
The reactions were carried out at 30°C in 1 ml of the standard medium with 0.8 mg
protein. 50 µM Aβ25–35 was incubated five minutes before succinate addition.
25 nmolmg protein FCCP was added one minute after mitochondria energization.
Mitochondrial Calcium Fluxes
Mitochondrial calcium fluxes were measured by monitoring the changes in Ca2+
concentration in the reaction medium using a calcium-selective electrode according
to previously described procedures (Moreno and Madeira, 1991). The reactions were
conducted in an open vessel with magnetic stirring in 1 ml of the reaction medium
containing 100 mM sucrose, 100 mM KCl, 2 mM KH2PO4 , 10 µM EGTA, 5 mM
Hepes (pH 7.4), with 2 µM rotenone. Mitochondria (0.8 mgml) were energized with
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5 mM succinate after one minute of Ca2+ addition in the absence and in the presence
of Aβ25–35 (50, 100 µM) and 0.85 µM CsA or 1 mM ADP plus 2 µgml oligomycin.
RESULTS
Effect of Aβ25–35 on ∆Ψm: Induction of PTP
The mitochondrial electric potential (∆Ψm) drop is a typical phenomenon that
leads to the induction of PTP. In Fig. 1 we can observe the alteration of brain
∆Ψm induced by Aβ25–35. In control conditions (Fig. 1A), after the energization of
mitochondria with succinate, the first and second pulse of 125 nmol Ca2+ per mg of
protein led to a rapid depolarization followed by repolarization. However, a third
pulse of Ca2+ led to an irreversible depolarization of mitochondria after a smaller
repolarization. The collapse of the ∆Ψm is prevented by adding EGTA or oligo-
mycin plus ADP (data not shown) which further led to a complete restoration of the
Fig. 1. Effect of Aβ25–35 on mitochondrial membrane potential. Freshly isolated brain
mitochondria (0.8 mg) in 1 ml of the standard medium supplemented with 3 µM TPP+
and 2 µM rotenone were energized with 5 mM succinate. A. Ca2+ (125 nmolmg protein)
was added one minute after mitochondria energization. B., C. 50 µM Aβ25–35 and 100 µM
Aβ25–35, respectively, were pre-incubated for five minutes at 30°C before mitochondria
energization. The traces are typical of four or five experiments.
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∆Ψm to the state 4 level (e.g., before Ca2+ addition). In the presence of Aβ25–35
(50 µM and 100 µM) (Fig. 1B, C) a significant decrease of ∆Ψm, measured after
mitochondria energization, occurred. This decrease in ∆Ψm is more pronounced in
mitochondria pre-incubated with 100 µM Aβ25–35. These mitochondria were more
susceptible to the amount of Ca2+ added; apparently they undergo PTP in the pres-
ence of lower Ca2+ concentrations (after two Ca2+ challenges), when compared to
the control mitochondria. The drop in ∆Ψm and the increased susceptibility to Ca2+
were dependent on Aβ25–35 concentration.
The reverse sequence of Aβ25–35 (Aβ35–25) did not affect the ∆Ψm as compared
with control condition (Fig. 2).
Protection of 1∆Ψm Afforded by CsA and Oligomycin Plus ADP: Inhibition of PTP
Pre-incubation (two minutes) of mitochondria with 1 mM ADP plus 2 µgml
oligomycin afforded complete protection against mitochondrial membrane depolar-
ization, by increasing dramatically the capacity of mitochondria to repolarize the
membrane after Ca2+ accumulation (Fig. 3).
Additionally, cyclosporin A (CsA), when added two minutes prior to Ca2+ or
Aβ25–35, afforded a clear protection of mitochondria since it prevents the depolariz-
ation induced by of Ca2+ when Aβ25–35 is present.
Effect of Aβ25–35 and FCCP on ∆Ψm and Respiration
To distinguish between a direct or an indirect action of this peptide on PTP,
the effect of 25 nmolmg protein of FCCP (a mitochondrial respiratory chain
uncoupler) (Fig. 4B) was tested. The first pulse of 125 nmol Ca2+ per mg of protein
led to a rapid depolarization followed by an incomplete repolarization. However, a
second pulse of Ca2+ led to an irreversible depolarization, a profile similar to that
obtained with 50 µM Aβ25–35 (Fig. 4A).
Induction of PTP by Aβ25–35 is further evidenced by its effect on mitochondrial
respiration (Fig. 4). When the mitochondria were pre-incubated for five minutes
with 50 µM Aβ25–35, adding 125 µM Ca2+ resulted in a complete uncoupling of res-
piration which was traduced by a continuous stimulation of state 3 respiration. This
effect was similar to that exerted by FCCP, in the presence of 125 µM Ca2+.
Effect of Aβ25–35 on Calcium Fluxes
Since the mitochondrial collapse of ∆Ψm, associated to Ca2+ overload, is related
with PTP opening, experiments were performed to further confirm the Aβ25–35 induc-
tion of the PTP opening by studying the Ca2+ retention by energized mitochondria.
Figure 5A shows that isolated brain mitochondria incubated with 50 µM Ca2+
(125 nmolmg protein), in the presence of 2 mM phosphate and energized with succi-
nate, rapidly accumulate Ca2+ from the medium and, after a slow release of some of
the accumulated Ca2+, they were able to continue to accumulate Ca2+, thus retaining
a large portion of the Ca2+ present in the medium. In the presence of 100 µM Ca2+
mitochondria retained only a small amount of Ca2+. When Ca2+ was present in
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Fig. 2. Effect of Aβ35–25 on mitochondrial membrane potential. Freshly isolated brain mitochondria
(0.8 mg) in 1 ml of the standard medium supplemented with 3 µM TPP+ and 2 µM rotenone were
energized with 5 mM succinate. A. Ca2+ (125 nmolmg protein) was added one minute after mito-
chondria energization. B. 100 µM Aβ35–25 was pre-incubated for five minutes at 30°C before mito-
chondria energization. The traces are typical of three experiments.
higher doses (200–300 µM), mitochondria became unable to retain the accumulated
Ca2+ due to PTP opening. In fact, for 100 µM Ca2+, the addition of CsA or ADP
plus oligomycin, restored the ability of mitochondria to store Ca2+ by avoiding the
PTP opening (Fig. 5A).
The presence of Aβ25–35 potentiated the PTP opening (Fig. 5B, C). We also could
observe that the effect of Aβ25–35 on calcium fluxes was concentration-dependent,
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Fig. 3. Inhibitory effect of CsA and oligomycin plus ADP on
Aβ25–35-dependent permeability transition pore opening. Mito-
chondria were incubated at 0.8 mg proteinml under standard con-
ditions as described in Materials and Methods. 0.85 µM CsA and
1 mM ADP plus 2 µgml oligomycin were incubated with mito-
chondria for two minutes before adding Aβ25–35. The two Aβ25–35
(50 and 100 µM) were added five minutes before energizing the
mitochondria with 5 mM succinate. The traces are typical of four
or five experiments.
i.e., higher Aβ25–35 (100 µM) (Fig. 5C) led to a faster PTP opening and, consequently
to a smaller calcium retention within mitochondria. These effects on calcium
accumulation could be prevented in the presence of 0.85 µM CsA and 1 mM ADP
plus 2 µgml oligomycin. Although both agents contributed for a higher capacity of
mitochondria to accumulate Ca2+, the protection exerted by ADP plus oligomycin,
as occurred on ∆Ψm, was more effective than that exerted by CsA (Fig. 5C, D).
DISCUSSION
A potentially central factor in cell death in neurodegeneration is the PTP. This
channel has been shown to be involved in oxidant-induced mitochondrial large
amplitude swelling (Bernardi et al., 1994; Zoratti and Szabo, 1995), Ca2+ release
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Fig. 4. Effect of Aβ25–35 and FCCP on mitochondrial membrane potential and respiration.
Freshly isolated brain mitochondria (0.8 mg) in 1 ml of the standard medium supplemented
with 3 µM TPP+ and 2 µM rotenone were energized with 5 mM succinate. A. 50 µM Aβ25–35
was pre-incubated for five minutes at 30°C before mitochondria energization. B. 25 nM
FCCP was added one minute after mitochondria energization. The traces are typical of two
experiments.
(Bernardi et al., 1994), and cell death (Marchetti et al., 1996). Pore opening is con-
trolled by membrane voltage and affected by numerous agonists and antagonists.
Some of the effectors, which increase the PTP’s opening probability, include Ca2+,
Pi (Bernardi and Petronilli, 1996) oxidizing agents (Bernardi et al., 1994; Zoratti
and Szabo, 1995), atractyloside, and inhibitors of the electron transport chain (Cher-
nyak and Bernardi, 1996).
Several studies have demonstrated the existence of PTP in brain mitochondria
(Andreyev and Fiskum, 1999; Kim et al., 1999; Berman et al., 2000; Brustovetsky
and Dubinsky, 2000; Kristia´n et al., 2000). Preliminary evidence from experiments
with isolated brain mitochondria (Kristal and Dubinsky, 1997) and neuronal cul-
tures (Dubinsky and Levi, 1998) suggests that neuronal mitochondria can undergo
an increase in membrane permeability transition under pathological conditions.
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Fig. 5. Effect of Aβ25–35 on calcium fluxes. Mitochondria were incubated at 0.8 mg protein
ml under standard conditions as described in Materials and Methods. A. Standard medium
was supplemented with different Ca2+ concentrations (50, 100, 200, 300 µM) one minute before
mitochondria energization with 5 mM succinate. B., C. 50 and 100 µM Aβ25–35 , respectively,
were pre-incubated for five minutes before 100 µM Ca2+ addition. 0.85 µM CsA and 2 µgml
oligomycin plus 1 mM ADP were added to the reaction medium two minutes prior to Ca2+ or
Aβ25–35 pre-incubation. The uptake and release of sequestered Ca2+ by mitochondria were
monitored as described in Materials and Methods. The traces are typical of three experiments.
In this work, we demonstrate the involvement of Aβ on the promotion of brain
PTP induced by Ca2+. The mitochondrial ∆Ψm, mitochondrial respiration and cal-
cium fluxes were the parameters studied since they are hallmarks of PTP. Mito-
chondrial depolarization favors PTP induction, presumably by lowering thresholds
for calcium or oxidants (Bernardi, 1992). Extensive calcium cycling, the continual
movement of calcium into mitochondria via the calcium uniporter and out of the
mitochondria via the Na+Ca2+ exchanger, can also depolarize mitochondria and
lead to a membrane permeability transition (Kristal and Dubinsky, 1997). Similarly
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to other studies (Kristal and Dubinsky, 1997; Berman et al., 2000; Kristia´n et al.,
2000) we observe PTP induction by extramitochondrial calcium addition. Ca2+
uptake is concentration-dependent, with higher concentrations leading to a lower
amount of Ca2+ being accumulated by mitochondria, indicating a continuous cycling
of Ca2+ due to PTP induction. However, there was always a retention of some
amount of Ca2+ (Fig. 5) indicating that some mitochondria did not undergo PTP.
Kristia´n et al. (2000) using succinate as substrate observed that, in brain mitochon-
dria, following saturation of the Ca2+ uptake system, a large release of sequestered
calcium did not ocur.
Aβ25–35 decreased the ∆Ψm and the capacity of mitochondria to accumulate
Ca2+, accelerating PTP induction (Fig. 1B, C; Fig. 5B, C). Parks et al. (2001) demon-
strated that, in liver mitochondria, Aβ25–35 , in the presence of Ca2+ and phosphate,
induces PTP in a concentration-dependent manner. These results are in agreement
with other studies demonstrating that Aβ peptides can cause a harmful elevation of
intracellular calcium levels (Mattson et al., 1992). We observe that PTP induction is
potentiated in the presence of Aβ suggesting that Aβ establishes conditions pro-
moting calcium cycling, and thus, may predispose mitochondria to PTP induction
(Fig. 5B, C).
To elucidate between a direct or an indirect action of Aβ25–35 on PTP, we com-
pared the effect exerted by this peptide with that caused by the mitochondrial respir-
atory chain uncoupler FCCP. For this purpose, we used a small amount of FCCP
(25 nmolmg protein) in order to obtain a decrease in ∆Ψ similar that promoted by
Aβ25–35. Both agents, FCCP and Aβ25–35, produced a similar effect: diminished
∆Ψm, the capacity of mitochondria to accumulate Ca2+ (Fig. 1B, C, 4A, B, 5B, C)
and led to a complete uncoupling of the respiration (Fig. 4A, B). Uncoupling refers
to loss of respiratory control, i.e., the proton gradient is no longer coupled to oxida-
tive phosphorylation. Since uncouplers destroy the capacity for ATP synthesis, they
are highly toxic compounds. There are numerous evidences (Mattson, 1997; Pereira
et al., 1999) indicating an imbalance on energetic metabolism induced by Aβ
peptides.
The reverse sequence of Aβ25–35 (Aβ35–25) did not induce the PTP (Fig. 2). This
result allows us to conclude that a specific sequence of amino acids is needed for the
induction of PTP. Mattson et al. (1993) stated that the ‘‘reverse sequence’’ Aβ35–25
is not cytotoxic. Also, in a cell-based assay, Aβ25–35 generated ROS whereas
Aβ35–25 is not cytotoxic. Furthermore, Aβ25–35 was able to initiate synaptosomal
lipoperoxidation, whereas Aβ35–25 had no effect (Butterfield et al., 1994).
In Fig. 5, we observed the accumulation–release–recuperation behavior of brain
mitochondria probably due to the heterogeneity of brain mitochondria population.
A more susceptible mitochondrial sub-population to toxic agents undergoes PTP
and releases Ca2+ which can be reuptaken by other mitochondria. The ∆Ψm data
(Fig. 1) also confirmed this heterogeneity: after the first Ca2+ challenge, a small drop
on ∆Ψm occurred, this drop being probably due to the injury of the mitochondrial
sub-population more susceptible to insults. This heterogeneity of brain mitochondria
population was previously reported (Berman et al., 2000; Kristia´n et al., 2000).
After Aβ25–35 andor Ca2+ induced depolarization, EGTA (a Ca2+-chelating
agent) and ADP (an inhibitor of PTP) plus oligomycin (prevents ADP phosphoryl-
ation) completely repolarized mitochondria (Fig. 1), an effect that has also been
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demonstrated by others (Hunter and Haworth, 1979; Zoratti and Szabo, 1995; Brus-
tovetsky and Dubinsky, 2000).
Another proof that Aβ25–35 promotes PTP induction is given by the protection
exerted by the immunosuppressant peptide and specific inhibitor of PTP, CsA. The
effect of CsA on the ability of brain mitochondria to accumulate Ca2+ was only
moderate when compared with the effects described for CsA on liver or muscle
mitochondria (Fontaine et al., 1998; Kristia´n et al., 2000). Similar effects of CsA
were also reported on cell lines (Murphy et al., 1996) and neuronal primary cultures
(Dubinsky and Levi, 1998). Although CsA does not give a total protection against
PTP induction, it increases the capacity of brain mitochondria to accumulate Ca2+
(Figs. 3, 5). However, when ADP plus oligomycin were present initially, the Aβ25–
35 andor Ca2+-induced depolarization was prevented. Brustovetsky and Dubinsky
(2000) also reported the protection exert by ADP plus oligomycin on brain mito-
chondria before calcium challenge.
Our data clearly shows that the specific amino acid sequence Aβ25–35, affects
directly mitochondria leading to the uncoupling of respiration and, consequently, to
promotion of PTP, thus contributing to neuronal death. The understanding of the
mechanisms underlying the neurogenerative process induced by Aβ peptide is a
fundamental step for the finding of new therapeutical strategies in Alzheimer’s
disease.
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